BLSH-01 is under clinical development by MOA Life Plus and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BLSH-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BLSH-01 overview
BLS-PGA-C10 is under development for the treatment of cervical intraepithelial neoplasia, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and unspecified cancer. The drug candidate constitutes of poly gamma glutamic acid. The drug candidate is developed based on HumaMax Technology.
MOA Life Plus overview
MOA Life Plus operates a medicine and consumer business in South Korea that distributes medicines and medical supplies. Its consumer business manufactures and sells health functional foods and functional cosmetics. The company’s pipeline products include BLS-H01, which treats cervical dysplasia treatment, anticancer drug; BLS-M07 for cervical cancer treatment and BLS-M22, which targets Duchenne muscular dystrophy treatment. it offers P53, a target anti-cancer drug as well as health-functional food products, raw materials and other prescription drugs. Bioleaders is headquartered in South Korea.
For a complete picture of BLSH-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
